This study involves a number of different medications.
GSK3359609 is an experimental immunotherapy drug that targets a potential anti-cancer molecule called ICOS. The medication works by stimulating the body’s own immune system to target and destroy cancer cells.
Tremelimumab is also an immunotherapy drug – it works via the same mechanism as an existing kidney cancer treatment called Ipilimumab (Yervoy®)
This study will investigate the safety and effectiveness of GSK3359609 and Tremelimumab when used in combination. Different doses of GSK3359609 will be tested to determine the optimal dosage of this medication.
This study is specifically designed for patients with advanced kidney cancer who have completed standard therapy and whose cancer has continued to grow despite treatment.
- Clear cell kidney cancer
- Cancer has spread or cannot be removed by surgery
- Must have completed all standard therapies
- Must be able and willing to undergo a tumour biopsy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Aaron Hansen||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOttawa Hospital Cancer Centre||Principal InvestigatorDr. John Hilton||LocationOttawa, ON||Trial StatusRecruiting|